Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

THOUSAND OAKS, Calif. , Oct. 25, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of the U.S. financial markets.

AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS

AbbVie

Franklin Resources

Chevron

Helmerich & Payne

Old Republic International

Walgreens

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Best Retirement Stocks to Buy Now

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Amgen (AMGN) to Report Q3 Earnings: Will It Beat Estimates?

Akamai Technologies

Allstate

Arista Networks

Axon Enterprise

Cboe Global Markets

Constellation Energy Corp

Diamondback Energy

Humana

Eli Lilly

McKesson

Marathon Petroleum

NRG Energy

Progressive

Don't assume that all S&P 500 stocks are struggling. A small group are actually thriving, thank you.

Investors Scurry To Buy 14 Soaring Stocks As Market Sells Off

THOUSAND OAKS, Calif. , Oct. 24, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the fourth quarter of 2023.

AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND

Amgen Inc. (NASDAQ:AMGN ) Amgen Conference Call Following European Society for Medical Oncology Congress 2023 October 24, 2023 8:00 AM ET Company Participants David Reese – Executive Vice President-Research and Development Taofeek Owonikoko – Division Chief-Division of Hematology-Oncology, UPMC Hillman Cancer Ctr. Tarlatamab Jean-Charles Soria – Senior Vice President-Research and Development Kevin Kelly – Chair, Department of Medical Oncology, Sidney Kimmel Medical College Conference Call Participants Salveen Richter – Goldman Sachs Jay Olson – Oppenheimer Gregory Renza – RBC Capital Markets David Risinger – Leerink Partners Geoff Meacham – Bank of America Evan Seigerman – BMO Capital Markets Colin Bristow – UBS Alice Nettleton – Wolfe Research Dane Leone – Raymond James Leon Wang – Barclays Operator Hello.

Amgen Inc. (AMGN) Amgen Conference Call Following European Society for Medical Oncology Congress 2023 Transcript

When massive acquisitions take place, job cuts typically follow. Such is the case with Amgen (NASDAQ: AMGN ) today.

Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Gilead Sciences

Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.

3 Biotech Stocks With Decent Dividend for a Steady Return

First Global Phase 3 Study in Patients with Chemorefractory KRAS G12C - Mutated Metastatic Colorectal Cancer Results Featured in a Presidential Symposium at ESMO and Simultaneously Published in the New England Journal of Medicine (NEJM) THOUSAND OAKS, Calif. , Oct. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® (sotorasib) (960 mg or 240 mg) in combination with Vectibix® (panitumumab).

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC Late-Breaking Data Presented at ESMO and Published in the New England Journal of Medicine (NEJM)   Tarlatamab is an Investigational Delta-Like Ligand 3 (DLL3) Targeting BiTE® Molecule THOUSAND OAKS, Calif. , Oct. 20, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting BiTE® (bispecific T-cell engager) molecule, in patients with advanced stage small cell lung cancer (SCLC) who had failed two or more prior lines of treatment.

AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER

THOUSAND OAKS, Calif. , Oct. 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m.

AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023

Biogen

GlaxoSmithKline

Prothena

Vertex Pharmaceuticals

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

Archer-Daniels-Midland Company

Aflac

Allegion

Broadcom

Becton, Dickinson and Co.

Dover

Con Ed

Embecta Corp

Emerson Electric

W.W. Grainger

Johnson & Johnson

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

PepsiCo

Pfizer

Southern Company

T. Rowe Price Group

Trane Technologies plc

With the start of the final quarter of 2023, it's time to take a look back at my previous month of dividend income. Getting close to that $2,000 milestone in a month sure looks amazing. I know, those end of quarter months are always the big payers but it's still nice to see.

Dividend Income Update September 2023

Puma Biotechnology

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Amgen (AMGN). But which of these two stocks is more attractive to value investors?

PBYI vs. AMGN: Which Stock Is the Better Value Option?

Results From Phase 2 DeLLphi-301 Trial Highlight Potential of Tarlatamab, First BiTE in Patients With Previously Treated SCLC Pivotal Phase 3 CodeBreaK 300 Study Data Support LUMAKRAS® (sotorasib) Plus Vectibix® (panitumumab) Combination in KRAS G12C-Mutated mCRC Early-Stage Results for AMG 509 (xaluritamig) Illustrate Expanding Potential of Amgen's T-Cell Engagers in mCRPC THOUSAND OAKS, Calif. , Oct. 16, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid.

AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023

Abbott Labs

There is more to the comparison, and in the sections below, we discuss why we believe ABT will offer better returns than AMGN in the next three years.

Which Is A Better Pick – Abbott Stock Or Amgen?

Horizon Pharma

We believe that AMGN has overpaid for HZNP's pipeline, since most of its upside potential is attributed to price increases instead of the expanding TAM. The growing debt may also pose headwinds to its profitability and subsequently, dividend growth and balance sheet deleveraging. Then again, it appears that Mr. Market is still convinced about AMGN' profitable growth ahead, as demonstrated by the stock's immense bullish support.

Amgen: Horizon's Pipeline May Be Too Expensive

Amgen finally closed its acquisition of Horizon Therapeutics despite a regulatory hiccup. Horizon has a relatively impressive portfolio although, like Amgen, it has growth issues.

Is This Dividend Stock a Screaming Buy After Its Latest Acquisition?

In the closing of the recent trading day, Amgen (AMGN) stood at $285.04, denoting a +0.51% change from the preceding trading day.

(AMGN) Rises As Market Takes a Dip: Key Facts

A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).

Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade

Centene

UnitedHealth Group

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling.

Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks

Amgen stock snagged an upgrade Wednesday and surged to a 10-month high as one analyst examined the biotech behemoth's post-Horizon future.

Amgen Stock Surges To 10-Month High, Up 5% On An Unexpected Upgrade

Amgen Inc.'s AMGN, -0.11% pipeline of cancer, obesity and cardiovascular drugs is poised to deliver good news for the stock, analysts say, despite the company's recent setback with cancer drug Lumakras.

Amgen's cancer-drug pipeline looks promising despite FDA setback, analysts say

News for Amgen Stock (AMGN)